Compare Novo Nordisk A/S (NVO) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PulteGroup, Inc. — how do they compare? Novo Nordisk A/S trades at $45.07 (market cap $198.57B), while PulteGroup, Inc. trades at $118.95 (market cap $22.65B). The key difference: Novo Nordisk A/S is far larger — about 8.8× PulteGroup, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| NVO | PHM | |
|---|---|---|
Market Cap | $198.57B | $22.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $142.56 |
52-Week Low | $35.29 | $110.11 |
Enterprise Value | $213.37B | $23.07B |
Dividend Yield | 4.03% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
PulteGroup (PHM) trades at $120.07, down 3.52% on the day, reflecting recent market pressure amid rising bond yields and mortgage rates. The stock shows mixed technical signals with a bearish moving average trend but oversold RSI levels. Fundamentally, PHM maintains solid profitability with a net margin of 11.62% and ROE of 14.9%, though recent quarters saw two EPS misses. The company continues expansion in Florida and declared a $0.26 quarterly dividend, payable October 2, 2026.
The outlook is cautious near-term due to housing affordability concerns, but PHM's valuation appears reasonable with a P/E of 12.26. Analyst consensus leans bullish with a $137.57 price target, suggesting 14.6% upside. Key risks include interest rate sensitivity and economic slowdown impacts on homebuyer demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
